Partial-onset seizures (also known as focal seizures) are a type of epilepsy that affect a specific area of the brain. The symptoms of these seizures vary depending on the part of the brain affected, but can include muscle contractions, sensory changes, and altered consciousness.
The market for medications to treat partial-onset seizures is a significant one, with a number of different drugs available. Some of the most commonly used medications for partial-onset seizures include:
- Levetiracetam (brand name Keppra): This medication is used to treat partial-onset seizures in adults and children.
- Carbamazepine (brand name Tegretol): This medication is used to treat partial-onset seizures in adults.
- Lamotrigine (brand name Lamictal): This medication is used to treat partial-onset seizures in adults and children.
- Oxcarbazepine (brand name Trileptal): This medication is used to treat partial-onset seizures in adults and children.
- Topiramate (brand name Topamax): This medication is used to treat partial-onset seizures in adults and children.
The global market for antiepileptic drugs (AEDs), which includes medications used to treat partial-onset seizures, was valued at approximately $4.4 billion in 2020 and is expected to reach $6.3 billion by 2027, growing at a compound annual growth rate (CAGR) of 5.1% during the forecast period. The market is driven by the increasing prevalence of epilepsy and rising demand for AEDs, as well as the introduction of new drugs and increasing adoption of combination therapies.
However, the market is also highly competitive, with a number of established players such as UCB Pharma, Eisai, Pfizer, and GlaxoSmithKline, as well as a number of smaller players. Additionally, there is increasing competition from generic drugs, which are often less expensive and may be preferred by patients and healthcare providers.
Download Free Sample Copy of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4708
Key findings of the Partial-Onset Seizures market study:
- Regional breakdown of the Partial-Onset Seizures market based on predefined taxonomy.
- Innovative manufacturing processes implemented by Partial-Onset Seizures vendors in detail.
- Region-wise and country-wise fragmentation of the Partial-Onset Seizures market to grasp the revenue, and growth outlook in these areas.
- Changing preferences among consumers across various regions and countries.
- Factors (Positive and Negative) impacting the growth of the global Partial-Onset Seizures market.
- Partial-Onset Seizures price, market share, and Trends forecast for assessment period 2019-2029
Partial-onset Seizures Market: Segmentation
The partial-onset seizures market can be segmented into indication, drug type, distribution channels and geography.
Based on indication, the global partial-onset seizures market is segmented as:
- Simple Focal Seizures
- Complex Focal Seizures
- Secondary Generalized Seizures
Based on drug class, the global partial-onset seizures market is segmented as:
- First-line Anti-epileptics
- Carbamazepine
- Lamotrigine
- Levetiracetam
- Oxcarbazepine
- Sodium Valproate
- Adjunctive Anti-epileptics
- Clobazam
- Gabapentin
- Topiramate
Based on generation of drug, the global partial-onset seizures market is segmented as:
- First Generation Anti-epileptics
- Second Generation Anti-epileptics
- Third Generation Anti-epileptics
Based on the distribution channels, the global partial-onset seizures market is segmented as:
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- Online Pharmacies
Competitive Landscape
The Partial-Onset Seizures industry is dominated by some prominent players including
GlaxoSmithKline plc., Pfizer Inc., Abbott Laboratories, Novartis AG, Mylan N.V., Eisai Co., Ltd., SK Life Science Inc. Aprecia Pharmaceuticals, Dr. Reddy’s Labs Ltd., Cipla, Lupin Ltd., and among others.
The competition in the sector is driven by key parameters such as product price, targeted customer base, and strategic marketing. Major players in the market focused on the Partial-Onset Seizures market innovation by investing more in research and development. Furthermore, the industry players are focusing on the extensive usage of online distribution channels for enhanced cost-effectiveness. The sustainability in the supply chain is a decisive factor for Partial-Onset Seizures brands leading to an impact on the margin profits of firms.
Report Benefits & Key Questions Answered
- Partial-Onset Seizures Company & brand share analysis: Company and brand share analysis on Partial-Onset Seizures reveals how much market share is captured by Tier 1, Tier 2, and Tier 3 players
- Partial-Onset Seizures Historical volume analysis: The industry analysis provides data & insights on historical volume sales of Partial-Onset Seizures
- Partial-Onset Seizures Category & segment level analysis: Fact.MR’s Partial-Onset Seizures sales outlook offers category and segment level analysis on lucrative and nascent product types. Market players can use this information to identify sales potential and set sales targets at local, country, and regional level.
- Partial-Onset Seizures Consumption by demographics: The market intelligence study provides consumption by demographics analysis so market players can design their product and marketing strategies on the basis of high-value consumers
- Post COVID consumer spending on Partial-Onset Seizures: The report includes post COVID consumer spending analysis. This information will help business leads understand the shifts in purchasing power and behavior
- Manufacturing trend analysis: Vital information on how market players are aligning their manufacturing strategies with respect to evolving consumer sentiments
Interested to Procure The Data? Inquire here at – https://www.factmr.com/checkout/4708
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.com
